The effects of aprotinin on outcome from cerebral ischemia in the rat

Anesthesia and Analgesia

Volumn 88, Issue 1, 1999, Pages 1-7

  Grocott, Hilary P ^a   Sheng, Huaxin ^a   Miura, Yoshihide ^a   Sarraf Yazdi, Shiva ^a   Mackensen, G Burkhard ^a   Pearlstein, Robert D ^a   Warner, David S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APROTININ; ARTERIAL OCCLUSIVE DISEASES; CELL DEATH; CEREBRAL INFARCTION; HIPPOCAMPUS; ISCHEMIC ATTACK, TRANSIENT; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SERINE PROTEINASE INHIBITORS;

EID: 0032902461     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199901000-00001     Document Type: Article

References (38)

1. Royston D. High dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992;6: 76-100.
2. Hardy J-F, Belisle S. Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency. Can J Anaesth 1994;41:1104-12.
3. Hill G, Diego R, Stammers A, et al. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg 1998;65:66-9.
4. Hill G, Alonso A, Spurzem J, et al. Aprotinin and methylprednislone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;100:1658-62.
5. Levy J, Pifarre R, Schaff H, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion inpatients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236-44.
6. Levy J, Ramsay J, Murkin J. Aprotinin reduces the incidence of strokes following cardiac surgery [abstract]. Circulation 1996; 94:I-535.
7. Gionet T, Warner D, Verhaegen M, et al. Effects of intraischemic blood pressure on outcome from 2-vessel occlusion forebrain ischemia in the rat. Brain Res 1992;586:188-94.
8. Combs D, D'Alecy L. Motor performance in rats exposed to severe forebrain ischemia: effect of fasting and 1,3-butanediol. Stroke 1987;18:503-11.
9. Gionet T, Thomas J, Warner D, et al. Forebrain ischemia induces selective behavioral impairments associated with hippocampal injury in rats. Stroke 1991;22:1040-7.
10. Zea Longa E, Weinstein P, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
11. Memezawa H, Minamisawa H, Smith M, Siesjö B. Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp Brain Res 1992;89:67-78.
12. Yamamoto M, Tamura A, Kirino T, et al. Behavioral changes after focal cerebral ischemia by left middle cerebral artery occlusion in rats. Brain Res 1988;452:323-8.
13. Bederson J, Pitts L, Tsuji M, et al. Rat middle cerebral artery occlusion evaluation of the model and development of a neurologic examination. Stroke 1986;17:472-6.
14. Kraut E, Frey E, Werle E. Über die Inaktivierung des Kallikreins. Hoppe Seylers Zeitschr Physiolog Chem 1930;192:1-21.
15. Kunitz M, Northrop J. Isolation from beef pancreas of crystalline trypsinogen, trypsin, trypsin inhibitor, and an inhibitor trypsin compound. J Gen Physiol 1936;19:991-1007.
16. Harke H, Gennrich M. Aprotinin-ACD-blood. I. Experimental studies on the effect of aprotinin on the plasmatic and thrombolytic coagulation. Anaesthetist 1980;29:266-76.
17. Lord R, Roath O, Thompson J, et al. Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg 1992;79:517-21.
18. Kim K-U, Kwon O-J, Jue D-M, et al. Pro-tumour necrosis factor cleavage enzyme in macorphage membrane/particulate. Immunology 1993;80:134-9.
19. Wachtfogel Y, Kuchich U, Hack C, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106:1-9.
20. Murkin J. Cardiopulmonary bypass and the inflammatory reponse: a role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997;11:19-23.
21. Trapnell J, Rigby C, Talbot C, et al. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177-82.
22. Drayton M, Kiernan J. Effects of aprotinin on organ cultures of the cerebellum of the adult rat. Exp Neurol 1973;39:381-8.
23. Davis H, Gascho C, Kiernan J. Action of aprotinin on the survival of adult cerebellar neurons in organ culture. Acta Neuropathol 1975;32:359-62.
24. Kamiyama T, Katayama Y, Kashiwagi F, Terashi A. The role of bradykinin in mediating ischemic brain edema in rats. Stroke 1993;24:571-6.
25. Aoki M, Jonas R, Nomura F, et al. Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest. Ann Thorac Surg 1994;58:146-53.
26. Yanamoto H, Kikuchi H, Okamoto S, et al. Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospam in rabbits. Neurosurgery 1992;30:351-6.
27. Yanamoto H, Kikuchi H, Sato M, et al. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administration in the acute stage after subarachnoid hemorrhage. Neurosurgery 1992;30:236-61.
28. Feuerstein G, Liu T, Barone F. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-α. Cerebrovasc Brain Metab Rev 1994;6:341-60.
29. Kogure K, Yamasaki Y, Matsuo Y, et al. Inflammation of the brain after ischemia. Acta Neurochir (Wein) Suppl 1996;66:40-3.
30. Feuerstein GZ, Wang X, Barone FC. Inflammatory gene expression in cerebral ischemia and trauma. Ann NY Acad Sci 1997; 825:179-93.
31. Juurlink B, Sweeney M. Mechanisms that result in damage during and following cerebral. Neurosci Biobehav Rev 1997;21: 121-8.
32. Takaoka S, Bart RD, Pearlstein R, et al. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. J Cereb Blood Flow Metab 1997;17:161-7.
33. Grocott H, Bart R, Sheng H, et al. Effects of a synthetic allosteric modifier of hemoglobin affinity on outcome from global cerebral ischemia in the rat. Stroke 1998;29:1650-5.
34. Levy J, Bailey J, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80: 1013-8.
35. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim Forsch 1983;33:479-94.
36. Warner D, Zhou J, Ramani R, Todd M. Reversible focal ischemia in the rat: effects of halothane, isoflurane, and methohexital anesthesia. J Cereb Blood Flow Metab 1991;11:794-802.
37. Saito R, Graf R, Hubel K, et al. Reduction of infarct volume by halothane: effect on cerebral blood flow or perifocal spreading depression-like depolarizations. J Cereb Blood Flow Metab 1997;17:857-64.
38. Slaughter T, LeBLeu T, Douglas J, et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6.